HealthCare Market Analysis

The global  breast lesion localization methods market  is expected to reach USD 1.57 billion by 2025, according to a new report by Grand View Research, Inc. The increasing government and non-government reimbursement policies for mammary gland cancer diagnosis, biopsy, pre-surgical examinations, and other treatment options is estimated to increase the adoption of breast lesion localization procedures. For instance, the Alabama Breast and Cervical Cancer Early Detection Program aims to provide breast and cervical oncology diagnostic and screening services to women who meet certain income, age, and insurance coverage eligibility guidelines. U.S. breast lesion localization methods, by type, 2014 - 2025 (USD Billion) Furthermore, rising prevalence of breast cancer is anticipated to propel the market growth. The disease is highly prevalent amongst women belonging to the age group of 65 years or above. The maximum risk of mammary gland cancer is between the age of 70 and 79. On

Electrophysiology devices industry  is anticipated to grow at a CAGR of over 5.0% and reach over USD 6.18 billion by 2020 owing to growing old age population and frequent cardiac arrhythmias incidents. Adoption of ablation and diagnostics techniques among physicians has resulted in increased usage of the product in the past few years and is likley to drive market growth. Development of new devices such as nanostimleadless pacemaker is also anticipated to fuel demand in the market.  Global electrophysiology devices market, by application, 2012 - 2020 (USD Million) Catherer ablation has gained popularity as the first line treatment, rendering 95.0% success rate for several rhythm disorders and is anticipated to be a key driving factor for growth. Diagnostic electrophysiology catheters are estimated to grow at the CAGR of over 15.0% in the foreseeable future.Technological developments such as laser ablation, cryo-ablation and ultrasound ablation, coupled with optimised ma

The global  rheumatoid arthritis therapeutics market  size is expected to reach USD 30.4 billion by 2025, according to a new report by Grand View Research, Inc., expanding at a CAGR of 4.6% during the forecast period. Some of the key trends driving the market are availability of novel biologics, increase in potential clinical pipeline candidates, and rise in aging population. Thus, growing availability and awareness of safer drugs are projected to escalate rheumatoid arthritis drugs market growth.  Rheumatoid arthritis affects approximately 1% of the global population. The condition has different symptoms such as joint pain, swelling, and stiffness, which are generally accompanied by chronic pain and inability to perform daily activities. Over a prolonged period, this disorder can hamper a patient’s mobility and can lead to permanent joint damage. If left untreated, this disorder can lead to mobility impairment and risk of joint replacement. Growing prevalence of the d